Table 3.

Stratified analyses of the 5 NPPA-NPPB polymorphisms with the risk of LVD in CAD patients with HLP under the additive genetic model

Study ID (rs number)	Group	Unadjusted			Adjusteda
		OR	95% CI	P value	OR	95% CI	P value
rs5065	HLP	–b	–	–	–	–	–
	Non-HLP	0.91	0.24-3.49	0.89	0.97	0.25-3.77	0.96
rs5063	HLP	0.69	0.28-1.71	0.42	0.69	0.26-1.81	0.45
	Non-HLP	1.24	0.82-1.88	0.31	1.19	0.78-1.82	0.41
rs632793	HLP	0.35	0.12-1.00	0.05	0.31	0.10-0.93	0.04
	Non-HLP	1.31	0.91-1.89	0.15	1.30	0.90-1.89	0.16
rs198388	HLP	0.30	0.10-0.86	0.03	0.26	0.09-0.79	0.02
	Non-HLP	0.99	0.69-1.40	0.93	0.97	0.68-1.39	0.86
rs198389	HLP	0.31	0.11-0.88	0.03	0.26	0.09-0.80	0.02
	Non-HLP	1.17	0.82-1.68	0.39	1.17	0.81-1.69	0.40

^aORs adjusted for age, gender, HTN, DM, Stroke history, smoking habit and angiographic profile.

^bdata not available.